Search tips
Search criteria 


Logo of medicinesLink to Publisher's site
Medicines (Basel). 2016 December; 3(4): 30.
Published online 2016 December 5. doi:  10.3390/medicines3040030
PMCID: PMC5456242

Identification of Phlogacantholide C as a Novel ADAM10 Enhancer from Traditional Chinese Medicinal Plants

James D. Adams, Academic Editor


Background: Alzheimer’s disease is one of the most prevalent dementias in the elderly population with increasing numbers of patients. One pivotal hallmark of this disorder is the deposition of protein aggregates stemming from neurotoxic amyloid-beta peptides. Synthesis of those peptides has been efficiently prevented in AD model mice by activation of an enzyme called alpha-secretase. Therefore, drugs with the capability to increase the expression of this enzyme, named ADAM10, have been suggested as a valuable therapeutic medication. Methods: We investigated 69 substances from a drug library derived from traditional Chinese medicine by luciferase reporter assay in human neuronal cells for their potential to selectively induce alpha-secretase expression. Western blot analysis was used to confirm results on the protein level. Results: Ten of the 69 investigated compounds led to induction of ADAM10 transcriptional activity while BACE-1 (beta-site APP cleaving enzyme 1) and APP (amyloid precursor protein) expression were not induced. Two of them—Norkurarinol and Phlogacantholide C—showed substantial elevation of ADAM10 protein levels and Phlogacantholide C also increased secretion of the ADAM10-derived cleavage product APPs-alpha. Conclusion: Phlogacantholide C represents a novel ADAM10 gene expression enhancer from traditional Chinese medicinal herbs that may lay the groundwork for evolving potential novel therapeutics in Alzheimer’s disease.

Keywords: ADAM10, Amyloid precursor protein, Alzheimer’s disease, Norkurarinol, Phlogacantholide C, Phlogacanthus curviflorus, Sophora flavescens

1. Introduction

As life expectancy in most civilizations has tremendously increased during the last 100 years, diseases of the advanced life period have come into the focus of research. Alzheimer’s disease is a slowly progressing neurodegenerative disease which is clinically characterized by cognitive decline and changes of personality [1]. An estimated 40 million people worldwide suffer from dementia, with Alzheimer’s disease being the most prevalent, at least in the elderly [2]. The origin of the disease still remains enigmatic despite the few genetically based cases (1%–3% of all cases [3]). This, as a consequence, hampers the development of efficient targeted medication. One molecular hallmark of the disease is the deposition of neurotoxic amyloid-beta peptides that derive from the proteolytic processing of the amyloid precursor protein (APP [4]) by beta-secretase BACE-1 and gamma-secretase [5,6]. However, involvement of these peptides has been controversially discussed in the field, and clinical trials which solely focused on preventing synthesis of the peptides have failed so far [7]. Targeting the alpha-secretase ADAM10 (a disintegrin and metalloproteinase 10) in this regard represents an attractive alternative: it not only prevents amyloid-beta generation by cutting within the respective peptide stretch but it also liberates the proteolysis fragment APPs-alpha [8]. The latter has been assigned beneficial effects for neuronal cells such as promoting outgrowth of neurites and preventing neuronal death as well as mitigating synaptic and cognitive deficits in AD (Alzheimer’s disease) mouse models [9,10,11,12].

Plant extracts have been used for more than 2000 years by indigenous populations for treating disorders including forms of dementia and memory impairment (as reviewed in [13]). Huge parts of the world’s population still rely on traditional medicine (TM) for their primary health care [14]: for example, in Korea as well as China 15.26% and 12.63% TM doctors practice in hospitals and clinics [15]. Western medicine shows increasing interest in isolating novel lead compounds from such traditionally used medications (reviewed in [16]). A recent example for a potential anti-AD therapeutic drug is given by caffeoylquinic acid, found, for example, in coffee beans, which has been shown to be protective against amyloid-beta–induced cytotoxicity and to reduce beta-sheet formation of amyloid-beta peptides in neuroblastoma cell lines [17,18]. In 2015 we described the identification of alpha-viniferin from the stem bark of Caragana sinica as an ADAM10 gene expression enhancer from a bank of traditional Korean medicinal plant extracts [19]. As part of the ongoing search for biologically active compounds from traditional Chinese medicine, we here report the investigation of a 69-compound-containing library which revealed the anti-amyloidogenic activity of Phlogacantholide C from Phlogacanthus curviflorus [20].

Phlogacanthus curviflorus (Wall.) Nees (Acanthaceae) is a large branched shrub which grows in Yunnan Province of China as well as, e.g., in Vietnam and India [21], and reaches up to 3 to 4 m. Oppositely arranged elliptic leaves are 8 to 10 in long. The tube-like reddish flowers are borne in upright spikes at the end of the branches. In North India, boiled leaf juice is used to cure cough and fever, and flowers are eaten raw or fried or used as a spice [22]. Moreover, it is used in the postpartum herbal bath of the Mien population in Northern Thailand, probably due to its antioxidant properties [23].

2. Materials and Methods

2.1. Plant Material

Medicinal plants were collected or purchased in China [24], mainly from Yunnan province (600 to 700 m above sea level). The botanical identification was done as described before [24] and voucher specimens deposited at the herbarium of the State Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming, Institute of Botany, Chinese Academy of Sciences, Kunming, P.R. China. The finely ground plant material was successively extracted with solvents of increasing polarity (petroleum ether (or n-hexane), ethyl acetate, and methanol) as described before [24,25] and finally solved in DMSO. For detailed information about the tested substances see [25].

2.2. Cell Culture

SH-SY5Y human neuroblastoma cells were maintained at humidified air (95%), 5% CO2 and 37 °C. Cultivation was performed using DMEM/F12 (Gibco, Fisher Scientific GmbH, Schwerte, Germany) supplemented with 10% fetal calf serum and 1% Glutamine. Cells were passaged twice a week 1:2–1:4.

2.3. Cytotoxicity Test

Potential cytotoxic effects were assessed by using the Cell Titer Glo-Assay (Promega, Mannheim, Germany) in 96-well formats (white plate with glass bottom). Initial drug concentration was 0.1% vol/vol in 50 μL culture medium and an incubation period of 48 h was tested. After 48 h of incubation, 50 μL of assay reagent were added and the ATP content (as a surrogate parameter for viability) measured using the Fluostar Optima luminometer (BMG Labtech, Cary, NC, USA). Ten measurements were taken from each well (interval time 0.5 s) and means calculated. Concentrations were adjusted if necessary (toxic or pro-proliferative effects) to obtain non-toxic dosages.

2.4. Transfection and Promoter Assays

A transient retro-cotransfection of two luciferase reporter plasmids (depending on ADAM10 or BACE-1 promoter activity) was conducted in SH-SY5Y cells as described previously [26]. In brief, to each well of a 96-well plate 20 μL Opti-MEM containing 100 ng of each luciferase encoding vector were added and incubated for 20 min at room temperature. Subsequently, 20 μL of Opti-MEM containing 0.3 μL transfection reagent (Lipofectamine 2000, Fisher Scientific GmbH, Schwerte, Germany) were added to each well and incubated for 45 min at room temperature. 1.5 × 105 cells per cm2 surface area of the dish were seeded. After 5 h of incubation, medium was exchanged to full cultivation medium containing DMSO (control) or the herbal drug in the indicated concentration and transfected cells were cultivated for 48 h. Cells were lysed in 20 μL passive lysis buffer (Promega), lysis promoted by freezing overnight at −20 °C and Renilla and firefly luciferase activity assessed using a reporter assay kit (Dual-Luciferase Reporter Assay, Promega) and the Fluostar Optima luminometer (BMG). The ratio of ADAM10-promoter activity (firefly luciferase) to BACE-1-promoter activity (Renilla luciferase) was calculated and the transcriptional activity of control cells was set to 100%. Hits were considered as follows: values > mean + SD (130%) of control-treated cells.

For the APP-promoter assay the procedure was comparable using a singular reporter vector based on the pGL4.76 plasmid (Promega) which has been describe before [26].

2.5. Western Blotting

For analysis of the drug-induced effect on ADAM10 expression and non-amyloidogenic APP-processing, cells were seeded on 24-well plates (1.3 × 105 cells per cm2 surface area) and incubated with the indicated drugs or DMSO for 48 h. Secretion medium was collected for the last 5 h following a medium exchange to FCS-free medium containing the respective drug or DMSO as a solvent. Secreted proteins were precipitated by trichloroacetic acid as described before (e.g., [27]). Cell lysates were prepared using Nu-PAGE-buffer (Fisher Scientific GmbH, Schwerte, Germany) supplemented with 10 vol % 1 M DTT. Samples were subjected to 8% SDS polyacrylamide gels and proteins separated at 70–120 V. Subsequently, proteins were transferred via tank blot procedure (2 h, 100 V, BioRad apparatus, Hercules, CA, USA) onto nitrocellulose membranes (blocked with 0.2% I-Block solution (Fisher Scientific GmbH, Schwerte, Germany) and incubated with the appropriate primary antibodies followed by secondary horse radish peroxidase-coupled antibodies (Fisher Scientific GmbH, Schwerte, Germany). Detection of signals was performed by CCD camera (Raytest, Straubenhardt, Germany) and densitometric analysis by Aida 3.5 (Raytest). Actin served as a loading control.

3. Results and Discussions

The collection and botanical identification of medicinal plants mainly from the Yunnan Province, China, have been described [24]. The bioactivity-guided isolation of phytochemicals by chromatographic methods was performed as previously described [28,29]. The chemical structures were elucidated by spectrometric methods and crystal structure analysis [30].

3.1. Results for Toxicity Assay

Starting from 0.1% vol/vol, 90% of the tested TCM (traditional Chinese medicine)-derived substances revealed no toxic effect on the human neuroblastoma cell line SH-SY5Y (61 out of 69, Figure 1). Only for a minority the concentration had to be reduced (only results from adjusted concentrations are presented, data from initial measurements with higher concentrations are not shown). For TCM19 (Sophoraflavon G) and TCM22 (Norkurarinol), for example, a further dilution to 0.01% evoked no viability-decreasing results. Sophoraflavanone G (5,7,2′,4′-tetrahydroxy-8-lavandulylflavanone), a close relative to Sophoraflavon G, has been referred to as a phytochemical with an intense antibacterial activity which might be due to its capability to reduce the fluidity of the outer and inner layers of membranes [31]. This was also assumed for Sophoraflavon G and thereby might explain the toxic effect on the human cells used in our study occurring at higher dosage. Norkurarinol, also a flavonoid extracted from Sophora flavescens, has been shown to exert cytotoxic effects in cancer cells, probably due to its tyrosinase inhibitor properties [32].

Figure 1
Toxicity assay of tested substances. SH-SY5Y cells were incubated for 48 h with 0.1% vol/vol substance and viability was assessed using the Cell Titer Glo assay. DMSO (solvent) and pure culture medium served as controls. Values ± SD were collected ...

3.2. Results for Dual Promoter Assay

TCM-derived substances were administered to the dual promoter assay for assessing the potential anti-amyloidogenic property. Ten out of the 69 tested substances revealed an ADAM10 promoter–inducing effect and none indicated an induction of BACE-1 promoter activity (Figure 2). The effect size was comparable for some substances to already known ADAM10 expression enhancers such as Acitretin or atRA [33,34], Wyf40, TCM22, 26, 47, 48, 49, 50, 88, while others displayed rather high induction rates (TCM19: 250% of control; TCM55: 207% of control). To make sure that none of the observed luciferase measurements was due to a direct effect on the enzymatic reaction, this was tested separately by an in vitro incubation of luciferase-containing cell lysate with the respective substance (data not shown).

Figure 2
Influence of tested substances on ADAM10/BACE-1 promoter activity ratio. Cells were incubated for 48 h with substances according to results from toxicity assay (see Figure 1). DMSO (solvent) and known activators of ADAM10 promoter activity (Acitretin ...

An ADAM10-enhancing effect with regard to Alzheimer’s disease should not be paralleled by an increase in the substrate expression itself. For instance, a higher gene dosage of APP alone is sufficient in Trisomy 21 patients to result in Alzheimer-type dementia [35]. Therefore, we tested if the nine candidates identified by the dual promoter assay inherit the inducing potential on the human APP promoter (see Table 1; TCM26 was not included due to lack of sufficient material for further analyses). None of the selected substances displayed a drastic induction or reduction of the APP transcriptional activity. APP promoter activity ranged from 117% to 61% of the control, but effects did not reach statistical relevance in comparison to solvent-treated cells.

Table 1
Candidate substances selected from dual promoter assay.

3.3. Results for ADAM10 Expression and Enzymatic Activity

Substance characterization based on reporter gene assays bears the problem of investigating an isolated DNA sequence without the genomic environment. Additionally, translation and stability of the protein products are not integrated in those investigations. We therefore analyzed the outcome of cultivating SH-SY5Y cells with the candidates from the dual promoter assay on the endogenous ADAM10 protein level (Figure 3A). For substances TCM22 (Norkurarinol) and 88 (Phlogacantholide C), the effect observed on the promoter construct was substantiated within the protein quantitation while those of the seven other compounds could not be substantiated: for TCM22 the immature proform of the enzyme was elevated to 132%, and the mature form to 137%. For TCM88 an induction to 143% for the proform and to 150% for the mature form was observed. For TCM88, additionally, an increase of APPs-alpha secretion of 200% as compared to solvent-treated cells was observed (Figure 3B). This indicates that not only the amount but also the activity of ADAM10 has been induced by Phlogacantholide C. We can only speculate why TCM22 failed to induce APPs-alpha secretion despite its effect on the ADAM10 amount: although we did not observe an influence on the APP promoter in our reporter gene assay, Norkurarinol might lead to a reduced APP protein amount at the cell surface or the newly built ADAM10 might be dislocated and therefore unable to cleave APP.

Figure 3
Influence of candidate substances on ADAM10 expression and APPs-alpha secretion. (a) Expression of ADAM10. Cells were incubated for 48 h with substances according to results from toxicity assay in FCS-containing medium (see Figure 1). DMSO (solvent) served ...

4. Conclusions

We identified Phlogacantholide C from Phlogacanthus curviflorus [20,36] as a new ADAM10 gene expression enhancer from a bank containing 69 substances derived from traditional Chinese medicinal herbs. Phlogacanthus curviflorus is used in traditional medicine as an anti-malarian drug [36] or in the context of curing or preventing inflammatory events [22,23]. However, no biological or pharmaceutical investigation regarding the isolated diterpene lactone glucoside has yet been reported to our knowledge.


This study was funded by a scholarship from the Focus Program Translational Neuroscience (FTN), University Medical CenterMainz, Germany, issued to F. Schuck.

Author Contributions

Author Contributions

Kristina Endres and Florian Schuck conceived and designed the project and wrote the manuscript; Thomas Efferth supervised collection and extraction of plant material and critically read the manuscript; Myriam Meineck performed the toxicity and reporter gene assays as well as the Western blots and analyzed the data; Sara Abdelfatah helped with preparing the table and with the structure description of the chemical compounds.

Conflicts of Interest

Conflicts of Interest

The authors declare no conflict of interest.


1. Chung J.A., Cummings J.L. Neurobehavioral and neuropsychiatric symptoms in Alzheimer’s disease: Characteristics and treatment. Neurol. Clin. 2000;18:829–846. doi: 10.1016/S0733-8619(05)70228-0. [PubMed] [Cross Ref]
2. Wimo A., Jonsson L., Bond J., Prince M., Winblad B. Alzheimer Disease International. The worldwide economic impact of dementia 2010. Alzheimers Dement. 2013;9:1–11. doi: 10.1016/j.jalz.2012.11.006. [PubMed] [Cross Ref]
3. Tanzi R.E. The genetics of Alzheimer disease. Cold Spring Harb. Perspect. Med. 2012;2:a006296. doi: 10.1101/cshperspect.a006296. [PMC free article] [PubMed] [Cross Ref]
4. Citron M., Diehl T.S., Gordon G., Biere A.L., Seubert P., Selkoe D.J. Evidence that the 42- and 40-amino acid forms of amyloid beta protein are generated from the beta-amyloid precursor protein by different protease activities. Proc. Natl. Acad. Sci. USA. 1996;93:13170–13175. doi: 10.1073/pnas.93.23.13170. [PubMed] [Cross Ref]
5. Vassar R., Bennett B.D., Babu-Khan S., Kahn S., Mendiaz E.A., Denis P., Teplow D.B., Ross S., Amarante P., Loeloff R., et al. Beta-secretase cleavage of Alzheimer’s amyloid precursor protein by the transmembrane aspartic protease BACE. Science. 1999;286:735–741. doi: 10.1126/science.286.5440.735. [PubMed] [Cross Ref]
6. Xia W., Zhang J., Ostaszewski B.L., Kimberly W.T., Seubert P., Koo E.H., Shen J., Selkoe D.J. Presenilin 1 regulates the processing of beta-amyloid precursor protein C-terminal fragments and the generation of amyloid beta-protein in endoplasmic reticulum and Golgi. Biochemistry. 1998;37:16465–16471. doi: 10.1021/bi9816195. [PubMed] [Cross Ref]
7. Iqbal K., Liu F., Gong C.X. Alzheimer disease therapeutics: Focus on the disease and not just plaques and tangles. Biochem. Pharmacol. 2014;88:631–639. doi: 10.1016/j.bcp.2014.01.002. [PMC free article] [PubMed] [Cross Ref]
8. Lammich S., Kojro E., Postina R., Gilbert S., Pfeiffer R., Jasionowski M., Haass C., Fahrenholz F. Constitutive and regulated alpha-secretase cleavage of Alzheimer’s amyloid precursor protein by a disintegrin metalloprotease. Proc. Natl. Acad. Sci. USA. 1999;96:3922–3927. doi: 10.1073/pnas.96.7.3922. [PubMed] [Cross Ref]
9. Fol R., Braudeau J., Ludewig S., Abel T., Weyer S.W., Roederer J.P., Brod F., Audrain M., Bemelmans A.-P., Buchholz C.J., et al. Viral gene transfer of APPsalpha rescues synaptic failure in an Alzheimer’s disease mouse model. Acta Neuropathol. 2016;131:247–266. doi: 10.1007/s00401-015-1498-9. [PubMed] [Cross Ref]
10. Gakhar-Koppole N., Hundeshagen P., Mandl C., Weyer S.W., Allinquant B., Muller U., Ciccolini F. Activity requires soluble amyloid precursor protein alpha to promote neurite outgrowth in neural stem cell-derived neurons via activation of the MAPK pathway. Eur. J. Neurosci. 2008;28:871–882. doi: 10.1111/j.1460-9568.2008.06398.x. [PubMed] [Cross Ref]
11. Hasebe N., Fujita Y., Ueno M., Yoshimura K., Fujino Y., Yamashita T. Soluble beta-amyloid Precursor Protein Alpha binds to p75 neurotrophin receptor to promote neurite outgrowth. PLoS ONE. 2013;8:e82321 doi: 10.1371/journal.pone.0082321. [PMC free article] [PubMed] [Cross Ref]
12. Hick M., Herrmann U., Weyer S.W., Mallm J.P., Tschape J.A., Borgers M., Mercken M., Roth F.C., Draguhn A., Slomianka L., et al. Acute function of secreted amyloid precursor protein fragment APPsalpha in synaptic plasticity. Acta Neuropathol. 2015;129:21–37. doi: 10.1007/s00401-014-1368-x. [PubMed] [Cross Ref]
13. Howes M.J., Houghton P.J. Ethnobotanical treatment strategies against Alzheimer’s disease. Curr. Alzheimer Res. 2012;9:67–85. doi: 10.2174/156720512799015046. [PubMed] [Cross Ref]
14. Zhang X. WHO Traditional Medicine Strategy 2002–2005. WHO; Geneva, Switzerland: 2002.
15. Park H.L., Lee H.S., Shin B.C., Liu J.P., Shang Q., Yamashita H., Lim B. Traditional medicine in China, Korea, and Japan: A brief introduction and comparison. Evid. Based Complement. Alternat. Med. 2012;2012:429103. doi: 10.1155/2012/429103. [PMC free article] [PubMed] [Cross Ref]
16. Kumar H., More S.V., Han S.D., Choi J.Y., Choi D.K. Promising therapeutics with natural bioactive compounds for improving learning and memory—A review of randomized trials. Molecules. 2012;17:10503–10539. doi: 10.3390/molecules170910503. [PubMed] [Cross Ref]
17. Gray N.E., Morre J., Kelley J., Maier C.S., Stevens J.F., Quinn J.F., Soumyanath A. Caffeoylquinic acids in Centella asiatica protect against amyloid-beta toxicity. J. Alzheimers Dis. 2014;40:359–373. [PMC free article] [PubMed]
18. Miyamae Y., Kurisu M., Murakami K., Han J., Isoda H., Irie K., Shigemori H. Protective effects of caffeoylquinic acids on the aggregation and neurotoxicity of the 42-residue amyloid beta-protein. Bioorg. Med. Chem. 2012;20:5844–5849. doi: 10.1016/j.bmc.2012.08.001. [PubMed] [Cross Ref]
19. Schuck F., Schmitt U., Reinhardt S., Freese C., Lee I.S., Thines E., Efferth T., Endres K. Extract of Caragana sinica as a potential therapeutic option for increasing alpha-secretase gene expression. Phytomedicine. 2015;22:1027–1036. doi: 10.1016/j.phymed.2015.08.001. [PubMed] [Cross Ref]
20. Yuan X.H., Li B.G., Zhang X.Y., Qi H.Y., Zhou M., Zhang G.L. Two diterpenes and three diterpene glucosides from Phlogacanthus curviflorus. J. Nat. Prod. 2005;68:86–89. doi: 10.1021/np0497999. [PubMed] [Cross Ref]
21. Hu Q., Chui H.B. Flora Yunnanica. Volume 1 Science Press; Beijing, China: 2006.
22. Phurailatpam A.K., Singh S.R., Chanu T.M., Ngangbam P. Phlogacanthus—An important medicinal plant of North East India: A review. Afr. J. Agric. Res. 2014;9:2068–2072.
23. Panyaphu K., On T.V., Sirisa-ard P., Srisa-nga P., Chansa Kaow S., Nathakarnkitkul S. Medicinal plants of the Mien (Yao) in Northern Thailand and their potential value in the primary healthcare of postpartum women. J. Ethnopharmacol. 2011;135:226–237. doi: 10.1016/j.jep.2011.03.050. [PubMed] [Cross Ref]
24. Efferth T., Kahl S., Paulus K., Adams M., Rauh R., Boechzelt H., Hao X., Kaina B., Bauer R. Phytochemistry and pharmacogenomics of natural products derived from traditional Chinese medicine and Chinese materia medica with activity against tumor cells. Mol. Cancer Ther. 2008;7:152–161. doi: 10.1158/1535-7163.MCT-07-0073. [PubMed] [Cross Ref]
25. Mahringer A., Karamustafa S., Klotz D., Kahl S., Konkimalla V.B., Wang Y., Wang J., Liu H.Y., Boechzelt H., Hao X., et al. Inhibition of P-glycoprotein at the blood-brain barrier by phytochemicals derived from traditional Chinese medicine. Cancer Genom. Proteom. 2010;7:191–205. [PubMed]
26. Reinhardt S., Schuck F., Grosgen S., Riemenschneider M., Hartmann T., Postina R., Grimm M., Endres K. Unfolded protein response signaling by transcription factor XBP-1 regulates ADAM10 and is affected in Alzheimer’s disease. FASEB J. 2014;28:978–997. doi: 10.1096/fj.13-234864. [PubMed] [Cross Ref]
27. Endres K., Postina R., Schroeder A., Mueller U., Fahrenholz F. Shedding of the amyloid precursor protein-like protein APLP2 by disintegrin-metalloproteinases. FEBS J. 2005;272:5808–5820. doi: 10.1111/j.1742-4658.2005.04976.x. [PubMed] [Cross Ref]
28. Wang J., Di Y., Yang X., Li S., Wang Y., Hao X. Hydroquinone diglycoside acyl esters from the stems of Glycosmis pentaphylla. Phytochemistry. 2006;67:486–491. doi: 10.1016/j.phytochem.2005.11.025. [PubMed] [Cross Ref]
29. Wang Y.F., Lai G.F., Efferth T., Cao J.X., Luo S.D. New glycosides from Tetracentron sinense and their cytotoxic activity. Chem. Biodivers. 2006;3:1023–1030. doi: 10.1002/cbdv.200690100. [PubMed] [Cross Ref]
30. Hu M., Chen J., Lin H. Metabolism of flavonoids via enteric recycling: Mechanistic studies of disposition of apigenin in the Caco-2 cell culture model. J. Pharmacol. Exp. Ther. 2003;307:314–321. doi: 10.1124/jpet.103.053496. [PubMed] [Cross Ref]
31. Tsuchiya H., Iinuma M. Reduction of membrane fluidity by antibacterial sophoraflavanone G isolated from Sophora exigua. Phytomedicine. 2000;7:161–165. doi: 10.1016/S0944-7113(00)80089-6. [PubMed] [Cross Ref]
32. Son J.K., Park J.S., Kim J.A., Kim Y., Chung S.R., Lee S.H. Prenylated flavonoids from the roots of Sophora flavescens with tyrosinase inhibitory activity. Planta Med. 2003;69:559–561. [PubMed]
33. Prinzen C., Muller U., Endres K., Fahrenholz F., Postina R. Genomic structure and functional characterization of the human ADAM10 promoter. FASEB J. 2005;19:1522–1524. doi: 10.1096/fj.04-3619fje. [PubMed] [Cross Ref]
34. Tippmann F., Hundt J., Schneider A., Endres K., Fahrenholz F. Up-regulation of the alpha-secretase ADAM10 by retinoic acid receptors and acitretin. FASEB J. 2009;23:1643–1654. doi: 10.1096/fj.08-121392. [PubMed] [Cross Ref]
35. Head E., Lott I.T., Wilcock D.M., Lemere C.A. Aging in Down Syndrome and the Development of Alzheimer’s Disease Neuropathology. Curr. Alzheimer Res. 2016;13:18–29. doi: 10.2174/1567205012666151020114607. [PMC free article] [PubMed] [Cross Ref]
36. Lai G.-F., Wang X.-Y., Wang Y.-F., Cao J.-X., Luo S.-D., Peng J. Diterpenes and Diterpene Glucosides from Phlogacanthus curviflorus. Helvetica Chim. Acta. 2009;92:470–480. doi: 10.1002/hlca.200800274. [Cross Ref]

Articles from Medicines are provided here courtesy of Multidisciplinary Digital Publishing Institute (MDPI)